Introduction
============

Cardiovascular disease (CVD) causes about one-third of all deaths for women worldwide,[@B1][@B2] and develops about 7 to 10 years later in women than men on average. The number of cardiovascular deaths for women increases after menopause.[@B2][@B3] Menopause accompanies unfavorable changes in serum lipoprotein concentrations because of a decrease in serum estrogen level.[@B4][@B5][@B6][@B7] Postmenopausal estrogen therapy has favorable effects on serum lipid, and has contributed to a decrease in the risk of CVD by 25% to 50%[@B8] and prevention of death by 50%.[@B8][@B9] Serum levels of total cholesterol, low-density lipoprotein (LDL) and lipoprotein(a) were reduced, while serum levels of high-density lipoprotein (HDL) and triglyceride were increased after oral administration of estrogen.[@B10] On the contrary, serum levels of total cholesterol, LDL and lipoprotein(a) were reduced, while serum levels of HDL and triglyceride remained the same after transdermal administration of estrogen.[@B11][@B12][@B13] With combined use of estrogen therapy, progestogens had different effects on HDL cholesterol depending on different types.[@B14][@B15] Although medroxyprogesterone acetate inhibits the effect of estrogen, micronized progesterone (MP) does not interfere with the increase of HDL level.[@B15] However, since most previous studies were done on Western women, only a limited number of studies have investigated serum lipoprotein cholesterol according to the route of estrogen administration and a combination of progesterone with estrogen in Korean women. This study was conducted to examine the effects of oral and thermal estrogen therapies on serum lipid levels and change of lipid profile of additionally administered MP in postmenopausal Korean women.

Materials and Methods
=====================

This retrospective study included 154 healthy postmenopausal Korean women who underwent hormone replacement therapy in the Menopause Clinic, Department of Obstetrics and Gynecology, Samsung Medical Center from April 1994 to December 2013. Menopause is defined as the cessation of menstruation for more than a year or serum follicle stimulating hormone (FSH) levels of 40 IU/L or higher. We excluded subjects taking any medication that can influence lipid profile or those with past history of CVD or risk factors of CVD (hypertension, diabetes mellitus, smoking and others). As hormone therapy, 65 women without a uterus were given estrogen alone (oral: 39, non-oral: 6), and 89 women were given estrogen in combination with MP (oral estrogen: 40, non-oral: 49). Conjugated equine estrogen 0.625 mg/day or equivalent medication were administered as oral estrogen, while 0.1% 17β-estradiol gel 1.5 mg/day was applied to the forearm as non-oral estrogen.

Serum levels of triglyceride, HDL and LDL cholesterol and lipoprotein (a) were measured after 14 hours of fasting on an empty stomach, and their changes were compared before, 3 and 6 months after hormone therapy. All statistical analyses were done using SPSS version 21.0 for windows (SPSS Inc., Chicago, IL, USA), and the data were presented as the mean ± standard deviation (SD). Statistical difference between two groups was compared with two-tailed unpaired student t-tests, chi-square analysis, and two-tailed paired student t tests. *P* values of less than 0.05 were considered statistically significant.

Results
=======

[Table 1](#T1){ref-type="table"} shows the baseline characteristics of estrogen alone and combined estrogen-progesterone therapy groups with oral hormone administration. Menopausal age was significantly older in the combined estrogen-progesterone therapy group. According to the analysis of lipid changes during 6 months, single administration of estrogen significantly decreased LDL and lipoprotein (a) levels and significantly increased triglyceride and HDL levels ([Table 2](#T2){ref-type="table"}). With combined administration of MP, serum cholesterol levels, excluding lipoprotein (a), showed same changes as single administration of estrogen. After adjusting menopausal age, changing pattern in serum cholesterol had no difference between two groups. Due to the nature of baseline characteristics of estrogen alone and combined estrogen-progesterone therapy groups with transdermal route of administration, menopausal age was significantly older in combined therapy group ([Table 3](#T3){ref-type="table"}). No significant change was observed in estrogen alone and combined therapy groups ([Table 4](#T4){ref-type="table"}).

Considering that combined use of MP did not influence the effect of estrogen on lipid profile based the above findings regardless of routes of hormone administration, a comparative analysis was performed by the route of estrogen administration by combining estrogen alone and combined estrogen-progesterone therapy groups. Although no difference was found in menopausal age between two groups, body mass index (BMI) was lower in oral administration group compared with transdermal administration group. In addition, a family history of CVD was more commonly noted in oral administration group ([Table 5](#T5){ref-type="table"}).

[Table 6](#T6){ref-type="table"} shows the comparison of serum cholesterol levels in whole hormone therapy group by the route of estrogen. A significant decrease was found in LDL and lipoprotein (a) levels and a significant increase was detected in triglyceride and HDL levels compared to the baseline levels in oral administration group. On the other hand, no significant change was observed in lipoprotein levels in transdermal administration group. After adjusting BMI and a family history of CVD, changing pattern of HDL was significantly different between two groups by administration route ([Fig. 1](#F1){ref-type="fig"}).

Discussion
==========

LDL cholesterol and lipoprotein (a) levels dropped and HDL and triglyceride levels increased significantly in oral administration group after 6-month hormone therapy. In contrast, no significant change was observed in transdermal administration group. In comparison of changes in lipoproteins during 6-month hormone therapy by administration route, changing pattern of HDL cholesterol was significantly different between two groups. This result is meaningful considering the fact that HDL is more important predictor of CVD than LDL in women.[@B3][@B16] Several previous studies have verified that estrogen administration has beneficial effects on serum lipid profile and cardiovascular protective effects in postmenopausal women.[@B8][@B9][@B17][@B18] The effects of estrogen on serum lipid profile are affected by administration route or addition of progesterone.[@B19] Oral estrogens are most commonly used modality, and their bioavailability is reduced, changes in serum estrogen levels are relatively large and there is the risk of side effects due to formation of by-products during gastrointestinal absorption and metabolism in the liver.[@B20] Since transdermal estrogen not metabolized in the liver flows into the blood vessels via passive diffusion through the skin, postmenopausal symptoms can be managed at a relatively low dose. However, transdermal estrogens have less impact on the lipid profile than oral estrogens.[@B21] According to the results of previous studies, oral estrogens have been shown to beneficially affect serum lipid profile by reducing LDL level and increasing HDL level, but may elevate serum triglyceride level. On the contrary, transdermal estrogens have less impact on lipoproteins compared to oral estrogens.

Even though the results of this study on the effects of oral administration are comparable to those of Western studies, a difference was found in the findings of previous studies that showed reduced LDL and elevated HDL levels after transdermal administration. This is thought to be attributable to racial differences in estrogen action.[@B22][@B23] The administration of oral estrogens might be more beneficial than transdermal hormone therapy in terms of serum lipid profile in postmenopausal Korean women.

MP co-administered with estrogen had no significant influence on estrogenic activity. Unlike medroxyprogesterone acetate, the study results aligned with the outcomes of previous studies that a significant increase of serum HDL level was maintained.[@B15][@B24] The combined use of MP is expected to be beneficial to endometrial protection in postmenopausal women with a uterus without attenuating the favorable effects of estrogen on serum lipid profile.

This study was meaningful in that it analyzed the effects on oral and transdermal hormone therapies on serum lipid profile in postmenopausal Korean women and the difference between with and without progesterone. This investigation was limited by the relatively small sample size as a retrospective study and a relatively short follow-up period of 6 months.

To sum up the above study result, hormone replacement therapy using oral estrogens clearly exerts favorable effects on lipoprotein metabolism in postmenopausal women. Moreover, the addition of MP does not attenuate these favorable effects of estrogen on serum lipid metabolism. Further studies with larger population samples of women are warranted.
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###### Baseline characteristics of oral hormone-therapy group by additional progesterone
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Data are presented as mean ± standard deviation or number (%)

^\*^*P* \< 0.05 indicates significant difference between two groups

CVD: cardiovascular disease

###### Comparison of serum cholesterol levels in oral hormone therapy group by progesterone, adjusted by menopausal age
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Data are presented as mean ± standard deviation or number (%)

^\*^*P* \< 0.05 indicates significant difference within the group

ET: estrogen therapy, EPT: estrogen / progesterone therapy

###### Baseline characteristics of transdermal hormone therapy group by additional protesterone
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^\*^*P* \< 0.05 indicates significant difference between two groups

###### Comparison of serum cholesterol levels in transdermal hormone therapy group by progesterone, adjusted by menopausal age
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###### Baseline characteristics of whole hormone therapy group by route of estrogen administration

![](jmm-21-104-i005)
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^\*^*P* \< 0.05 indicates significant difference between two groups
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###### Comparison of serum cholesterol levels in whole hormone therapy group by the route of estrogen, adjusted by body mass index and family history of cardiovascular disease
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